Despite their promise, these therapies have faced significant regulatory and access challenges. In July, the European ...
Bristol Myers Squibb gets positive CHMP opinion for Opdivo plus Yervoy to treat adult with MSI-H or dMMR metastatic colorectal cancer: Princeton, New Jersey Monday, November 18, 2 ...
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a ...
Interaksyon on MSN3h
‘Right of every Filipino’: Generic brand advocates for affordable healthcareHealthcare products provider RHEA Generics is committed to promoting affordable healthcare by offering generic medications ...
A new study reveals that more than half of cancer drugs approved by the FDA under accelerated pathways are not authorized in ...
Hosted on MSN2d
EU approves life changing 'important' Alzheimer's drug which can drastically slow onsetLecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...
Patients with MSI-high/dMMR advanced colorectal cancers had a 79 percent lower risk of disease progression or death on Opdivo-Yervoy compared to chemo.
The US Food and Drug Administration approved Augtyro in 2023 for the treatment of ROS1-positive advanced NSCLC. Earlier this year, the FDA also approved the drug for adult and pediatric patients 12 ...
The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...
Merck (MRK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion ...
Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.
Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback